8.05
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AUPH?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.04
Offen:
$8.01
24-Stunden-Volumen:
1.62M
Relative Volume:
1.21
Marktkapitalisierung:
$1.11B
Einnahmen:
$175.51M
Nettoeinkommen (Verlust:
$-78.02M
KGV:
-15.19
EPS:
-0.53
Netto-Cashflow:
$-34.18M
1W Leistung:
-7.15%
1M Leistung:
+1.26%
6M Leistung:
+10.88%
1J Leistung:
+49.07%
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Firmenname
Aurinia Pharmaceuticals Inc
Sektor
Branche
Telefon
250-744-2487
Adresse
#140, 14315 - 118 AVENUE, EDMONTON, BC
Vergleichen Sie AUPH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AUPH
Aurinia Pharmaceuticals Inc
|
8.05 | 1.11B | 175.51M | -78.02M | -34.18M | -0.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2022-11-04 | Herabstufung | Oppenheimer | Outperform → Perform |
2022-05-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2021-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
2021-01-25 | Bestätigt | H.C. Wainwright | Buy |
2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
2020-06-17 | Eingeleitet | BTIG Research | Buy |
2020-05-05 | Eingeleitet | Cowen | Outperform |
2020-01-10 | Eingeleitet | Jefferies | Buy |
2019-12-16 | Bestätigt | H.C. Wainwright | Buy |
2018-03-16 | Bestätigt | Cantor Fitzgerald | Overweight |
2018-02-08 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-10-30 | Bestätigt | H.C. Wainwright | Buy |
2017-05-18 | Bestätigt | H.C. Wainwright | Buy |
2017-04-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-03-22 | Bestätigt | FBR & Co. | Outperform |
2016-12-30 | Bestätigt | H.C. Wainwright | Buy |
2016-08-17 | Bestätigt | H.C. Wainwright | Buy |
2016-06-30 | Eingeleitet | H.C. Wainwright | Buy |
2015-05-08 | Eingeleitet | MLV & Co | Buy |
Alle ansehen
Aurinia Pharmaceuticals Inc Aktie (AUPH) Neueste Nachrichten
Little Excitement Around Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues - simplywall.st
Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March - Insider Monkey
(AUPH) Trading Signals - news.stocktradersdaily.com
Aurinia Pharmaceuticals Announces Financial Growth and Pipeline Progress in 2024 - Zenopa
Principal Financial Group Inc. Sells 1,325 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Aurinia Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Mainz Biomed Vs. Aurinia Pharma: Retail Traders Weigh In On The Better Biotech Bet - MSN
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome - MarketScreener
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 - Investing.com India
Aurinia Pharmaceuticals’ chief medical officer sells shares worth $68,350 By Investing.com - Investing.com UK
Commit To Purchase Aurinia Pharmaceuticals At $7, Earn 17.4% Annualized Using Options - Nasdaq
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting Point - Yahoo Finance
Aurinia Pharmaceuticals stock climbs on insider buying - MSN
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 - Investing.com Australia
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals CEO Peter Greenleaf sells shares worth $2.87 million - Investing.com India
Aurinia Pharmaceuticals CFO Joseph Miller sells shares worth $939,611 By Investing.com - Investing.com South Africa
Major Investment Alert: Kevin Tang Boosts Stake in Aurinia Pharmaceuticals - TipRanks
Aurinia Pharmaceuticals’ chief medical officer sells $97,912 in stock - Investing.com
Aurinia Pharmaceuticals COO Donley sells shares worth $994,424 - Investing.com India
Aurinia Pharmaceuticals EVP Stephen Robertson sells shares worth $975,223 - Investing.com
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? - Nasdaq
Objective long/short (AUPH) Report - Stock Traders Daily
LAWSUITS FILED AGAINST ABBV, SDIG and AUPHJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Atria Wealth Solutions Inc. Buys Shares of 15,000 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
Results: Aurinia Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Simply Wall St
Results: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Canada Finance
IFP Advisors Inc Raises Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong Earnings - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2024 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Regulatory and Financial Challenges Loom for Aurinia Pharmaceuticals Despite FDA and EC Approvals - TipRanks
Aurinia Pharmaceuticals Reports Strong 2024 Financial Growth - TipRanks
Aurinia Pharmaceuticals Reports Balanced Earnings with Growth and Challenges - TipRanks
Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations - Benzinga
Aurinia: Q4 Earnings Snapshot - CT Insider
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates - MSN
Earnings call transcript: Aurinia Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com
Aurinia Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aurinia Pharmaceuticals Swings to Q4 Earnings, Revenue Rises -February 27, 2025 at 09:26 am EST - Marketscreener.com
Aurinia Pharmaceuticals Reports Strong Financial Growth in 2024 - TipRanks
Aurinia Pharmaceuticals Files Form 8-K Indicating Key Corporate Event - TipRanks
Earnings Flash (AUPH) Aurinia Pharmaceuticals Reports Q4 Revenue $59.9M, vs. FactSet Est of $60.1M - Marketscreener.com
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q4 EPS $0.01, vs. FactSet Est of $0.02 Loss - Marketscreener.com
Aurinia Pharmaceuticals Inc. SEC 10-K Report - TradingView
Aurinia Pharma earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress - Business Wire
High Growth Tech Stocks In The United States Spotlighting Three Leaders - Yahoo Finance
Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? - Insider Monkey
Finanzdaten der Aurinia Pharmaceuticals Inc-Aktie (AUPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):